Now showing items 1-11 of 11

    • Bottje, Walter; Hargis, Billy; Berghman, Luc; Kwon, Young Min; Cole, Kimberly; Cox, Mandy; Layton, Sherryll (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2013-12-10)
      Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated ...
    • Bottje, Walter; Hargis, Billy; Berghman, Luc; Kwon, Young Min; Cole, Kimberly; Cox, Mandy; Layton, Sherryll (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2018-06-26)
      Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated ...
    • Barta, John R.; Berghman, Luc; Shivaramaiah, Srichaitanya; Faulkner, Olivia B.; Bielke, Lisa; Hargis, Billy (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2017-03-28)
      Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or morality associated with subsequent infection are provided herein. The vaccine ...
    • Barta, John R.; Berghman, Luc; Shivaramaiah, Srichaitanya; Faulkner, Olivia B.; Bielke, Lisa; Hargis, Billy (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2018-02-06)
      Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine ...
    • Barta, John R.; Berghman, Luc; Shivaramaian, Srichaitanya; Faulkner, Olivia B.; Bielke, Lisa; Hargis, Billy, (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2019-06-25)
      Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine ...
    • Barta, John R.; Berghman, Luc; Shivaramaiah, Srichaitanya; Faulkner, Olivia B.; Bielke, Lisa; Hargis, Billy (United States. Patent and Trademark Office; Texas A&M University. Libraries, 6/21/2022)
      Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine ...
    • Bottje, Walter; Hargis, Billy; Berghman, Luc; Kwon, Young Min; Cole, Kimberly; Cox, Mandy; Layton, Sherryll (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2015-09-08)
      Vaccines comprising fliC and CD 154 polypeptides and Salmonella enteritidis vaccine vectors comprising fliC polypeptides are provided. Also provided arc methods of enhancing an immune response against flagellated bacteria ...
    • Jackson, Francis C. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 1965-07-27)
    • Reddy, Sanjay M.; Lupiani, Blanca M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2020-01-21)
      The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions ...
    • Reddy, Sanjay M.; Lupiani, Blanca M. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2020-10-27)
      The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions ...
    • Samuel, James E.; Van Schaik, Erin J.; Gregory, Anthony E. (United States. Patent and Trademark Office; Texas A&M University. Libraries, 2021-04-06)
      A vaccine includes at least one bacterial antigen capable of producing an immune response in a host when the vaccine is administered at a dose that is sufficient for preventing or treating Q fever in the host. The vaccine ...